Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site

Cancer

Volumn 94, Issue 3, 2002, Pages 840-846

  Culine, Stphane ^a   Fabbro, Michel ^a   Ychou, Marc ^a   Romieu, Gilles ^a   Cupissol, Didier ^a   Pinguet, Frdric ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Chemotherapy; Granulocyte macrophage colony stimulating factor; Hematopoietic growth factor; Unknown primary carcinoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMA; CAUSE OF DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036469152     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10264     Document Type: Article

References (25)

1. Cancer of unknown primary site
2. Treatment of patients with cancer of an unknown primary site
3. Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy
4. Reporting results of cancer treatment
5. Nonparametric estimation from incomplete observations
6. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site
7. Responses of primary unknown cancers to treatment with 5-fluorouracil
8. Treatment of the patient with adenocarcinoma of unknown origin
9. Fluorouracil, adriamycin and mitomycin in the treatment of adenocarcinoma of unknown primary
10. Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients
11. Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary
12. Metastatic adenocarcinomas of unknown primary site: Prognostic variables and treatment results
13. Metastatic carcinoma of uncertain primary site: A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE)
14. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide
15. Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam)
16. Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site
17. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin
18. Carboplatin plus paclitaxel in unknown primary carcinoma: A Phase II Hellenic Cooperative Oncology Group study
19. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial
20. Metastatic adenocarcinoma of unknown primary site: A randomized study of two combination chemotherapy regimens
21. Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin
22. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience
23. Poorly differentiated neuroendocrine carcinoma of unknown primary tumor site
24. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary
25. Overexpression of Her-2 in patients with poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site